Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2

By sjmartinez • October 4, 2022

Finn RS, Yau T, Hsu CH, De Toni EN, Goyal L, Galle PR, Qin S, Rao S, Sun F, Wang C, Widau RC, Zhu AX. Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2. Oncologist. 2022 Oct 3:oyac183. doi: 10.1093/oncolo/oyac183. Epub ahead of print. PMID: 36190331.

Tags: advanced hepatocellular carcinoma (HCC), Digestive Diseases, non-sorafenib, Publications, ramucirumab, α-fetoprotein

Investigating shared genetic architecture between inflammatory bowel diseases and primary biliary cholangitis

Huang W, Jiang R, Li S, Zeng R, Li Y, Zhang Y, Tong S, Lyu Y, Wang J, Lian Q, Leung FW, Luo R, Sha[...]

Lower FIB-4 threshold in patients with diabetes improves diagnostic accuracy of the test in a Hispanic population

Singh J, Ibrahim B, Jackson NJ, Khalil H, Valenzuela J, Yanny B, Saab S. Lower FIB-4 threshold in patients with diabetes improves diagnostic accuracy of[...]

Role of the prefrontal cortical protease TACE/ADAM17 in neurobehavioral responses to chronic stress during adolescence

Sharafeddin F, Sierra J, Ghaly M, Simon TB, Ontiveros-Ángel P, Edelbach B, Febo M, Labus J, Figueroa JD. Role of the prefrontal cortical protease TACE/ADAM17[...]